RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for two related autoimmune conditions called Graves’ disease and thyroid eye disease. As part of the deal, RTW ...

Yarrow Bioscience (Nasdaq:YARW) reported second quarter 2026 results and progress on YB-101, its anti-TSHR antibody for Graves’ disease (GD) and thyroid eye disease (TED). The FDA granted Fast Track designation for YB-101 in GD, and a randomized Phase 2a/2b trial in GD (with or without TED) has been initiated, with 32 patients planned in Phase 2a and topline data expected in the second half of 2027. Licensing partner GenSci continues a Phase 1 MAD study in TED in China, with data anticipated in the second half of 2027.The company completed its reverse merger with VYNE Therapeutics, closed previously announced private financings totaling approximately $200 million, and began trading on Nasdaq as “YARW.” As of June 30, 2026, cash and cash equivalents were $18.7 million; together with $100 million received in July 2026, Yarrow expects to fund operations into 2028. Second quarter 2026 R&D expenses were $4.9 million, G&A expenses were $1.8 million, and net loss was $6.5 million. Following the merger, Yarrow has approximately 28.6 million common shares and equivalents outstanding.

Magelang, 22 Mei 2026 - Pendidikan sains pada jenjang sekolah dasar memegang peranan vital dalam membangun fondasi rasa ingin tahu, cara berpikir kritis, serta keberanian anak untuk bereksperimen. Namun, seringkali sains dianggap sebagai momok pelajaran yang rumit dan membosankan akibat dominasi metode teoretis di ruang kelas. Menjawab tantangan tersebut, GENSCI Indonesia hadir melalui program Workshop Anak Bangsa dengan mengusung tema “Dari Dasar Menuju Puncak Impian" di SD Negeri Tlogorejo, Kabupaten Magelang, pada Jumat, 22 Mei 2026. ​Kegiatan ini bertujuan untuk mengenalkan sains secara interaktif, menumbuhkan kreativitas, serta mengubah stigma bahwa sains adalah bidang ilmu yang kaku menjadi sesuatu yang sangat aplikatif dan menyenangkan.

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for Graves’ disease and thyroid eye disease.

RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for Graves’ disease and thyroid eye disease.